Policy

A CMS proposed rule would make the Medicare Drug Price Negotiation Program permanent, covering up to 20 drugs per year starting in 2029.

As drug research globalizes, regulators and trial designers must collaborate across regions to bring new treatments to patients.

ACA cancellations rise; HBV re-engagement varies by outreach; rural US has 44% fewer clinicians; diabetes and alopecia need custom care.

As GLP-1 approvals expand into new indications, claims data reveal most treated patients already qualify under multiple indications.

The authors evaluated changes in persistence to basal insulin in a Medicare Advantage population in the first year of the Medicare insulin out-of-pocket cost cap.

Four experts examine what updated dietary and obesity guidelines mean for diabetes care, and why personalized, equitable nutrition is now essential.

Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and policy barriers to equitable care.

At ADA 2026, Alyson K. Myers, MD, explains why knowing your community—and meeting patients where they are—is key to better diabetes outcomes and lower costs.

Cancer trauma, drug pricing claims, abortion cost gaps, insurance denials affecting 1 in 5, and food insecurity's economic toll top this week's roundup.

During a White House briefing, Mehmet Oz, MD, discussed the expansion of Trump Rx and crackdowns on duplicate ACA enrollment and fraudulent hospice programs.

The problem is not that price transparency itself has failed, but rather that policy makers have focused their efforts on the wrong place.

New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.

Abortion costs and Medicaid coverage vary by state, creating financial barriers for patients seeking care after the Dobbs v Jackson decision.

Accountable care offers one of the most promising frameworks for stabilizing and expanding access, but only if policy is intentionally designed to support rural participation.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

A survey of health care and life sciences executives found that the top challenges in the sectors included policy uncertainty and declining reimbursement rates.

A turbulent regulatory environment is forcing covered entities to rethink how they manage 340B compliance.

Claims data linked eviction protection rollbacks to higher psychotropic prescription and SMI visits, revealing housing security’s mental health toll.

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

The Trump administration fired USPSTF leaders, sparking concerns over the future of ACA-mandated free medical screenings and preventive care.

ACA enrollment drops 21.5% in 2026 after enhanced subsidies end. Deductibles hit record $3786 as enrollees shift to high-deductible bronze plans.

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

This study evaluated differences in racial and ethnic disparities in surgical outcomes between Medicare Advantage and traditional Medicare beneficiaries, finding consistent but nonuniform smaller disparities within Medicare Advantage.